

USTR Considers Removal of 301 Duties on COVID-19-Related Medical Care Products

Jennifer E. McCadney

March 25, 2020

In response to the COVID-19 outbreak, USTR issued a [Federal Register Notice](#) requesting public comments on the possibility of removing the application of China Section 301 duties from medical care products, including inputs used to produce such needed medical care products.

The **comment period will remain open until at least June 25, 2020**, however, USTR indicated the deadline may be extended. Interested parties are encouraged to submit comments as promptly as possible. Responses to comments should be submitted within three business days after a comment is posted on the docket. USTR will review requests and comments on a rolling basis.

The announcement further indicates that comments may be submitted regarding any product covered by Section 301 duties, even if the product is subject to a pending or denied exclusion request. Commenters must identify the product of concern and explain how it relates to the COVID-19 outbreak, including whether a product is directly used to treat COVID-19 or limit the outbreak, or whether the product is used in the production of needed medical-care products.

For additional information, please contact Jennifer McCadney.